JP2016521688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521688A5 JP2016521688A5 JP2016516198A JP2016516198A JP2016521688A5 JP 2016521688 A5 JP2016521688 A5 JP 2016521688A5 JP 2016516198 A JP2016516198 A JP 2016516198A JP 2016516198 A JP2016516198 A JP 2016516198A JP 2016521688 A5 JP2016521688 A5 JP 2016521688A5
- Authority
- JP
- Japan
- Prior art keywords
- exchanged
- replaced
- ankyrin repeat
- seq
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000009787 cardiac fibrosis Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 102000008102 Ankyrins Human genes 0.000 claims 37
- 108010049777 Ankyrins Proteins 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 102000014914 Carrier Proteins Human genes 0.000 claims 17
- 108091008324 binding proteins Proteins 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13170056.9 | 2013-05-31 | ||
| EP13170056 | 2013-05-31 | ||
| PCT/EP2014/061368 WO2014191574A1 (en) | 2013-05-31 | 2014-06-02 | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521688A JP2016521688A (ja) | 2016-07-25 |
| JP2016521688A5 true JP2016521688A5 (enExample) | 2018-10-18 |
| JP6486908B2 JP6486908B2 (ja) | 2019-03-20 |
Family
ID=48536726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516198A Active JP6486908B2 (ja) | 2013-05-31 | 2014-06-02 | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11453708B2 (enExample) |
| EP (1) | EP3004152B1 (enExample) |
| JP (1) | JP6486908B2 (enExample) |
| CN (1) | CN105209483B (enExample) |
| WO (1) | WO2014191574A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US20170226158A1 (en) * | 2014-08-11 | 2017-08-10 | Medimmune Limited | Intracellular antigen binding |
| US9458211B1 (en) * | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
| MY196882A (en) | 2016-09-22 | 2023-05-08 | Molecular Partners Ag | Recombinant binding proteins and their use |
| JP7380999B2 (ja) * | 2018-09-06 | 2023-11-15 | 国立大学法人 東京大学 | 環状ペプチド |
| GB201902392D0 (en) * | 2019-02-21 | 2019-04-10 | Cambridge Entpr Ltd | Modular binding proteins |
| JP2022535564A (ja) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| EP3980452A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| CA3139164A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| AU2021271131A1 (en) * | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| EP3957649A1 (en) * | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| WO2022061240A1 (en) * | 2020-09-21 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Heteromultimeric proteins for reducing ige-dependent allergic effector cell activation |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| US20240317852A1 (en) | 2021-03-09 | 2024-09-26 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| EP4137508A1 (en) * | 2021-08-17 | 2023-02-22 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CA3262553A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CN101189023B (zh) * | 2005-03-31 | 2013-01-30 | 通用医疗公司 | 监测和调制hgf/hgfr活性 |
| KR101268939B1 (ko) | 2005-07-08 | 2013-05-30 | 유니버시티 오브 취리히 | 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이 |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| EP2435478A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| MX2013005847A (es) * | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| SG11201408196RA (en) * | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
-
2014
- 2014-06-02 US US14/891,792 patent/US11453708B2/en active Active
- 2014-06-02 CN CN201480028078.2A patent/CN105209483B/zh active Active
- 2014-06-02 EP EP14727816.2A patent/EP3004152B1/en active Active
- 2014-06-02 WO PCT/EP2014/061368 patent/WO2014191574A1/en not_active Ceased
- 2014-06-02 JP JP2016516198A patent/JP6486908B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511327A5 (enExample) | ||
| JP2017048194A5 (enExample) | ||
| JP2017528117A5 (enExample) | ||
| CY1123978T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf | |
| JP2015522576A5 (enExample) | ||
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| JP2012511545A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2016529229A5 (enExample) | ||
| JP2019519216A5 (enExample) | ||
| WO2017189964A3 (en) | Compositions for the treatment of disease | |
| JP2019506841A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| JP2015227342A5 (enExample) | ||
| JP2019531093A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| JP2018510622A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| JP2016515524A5 (enExample) | ||
| JP2012507271A5 (enExample) | ||
| JP2014510519A5 (enExample) | ||
| JP2017532048A5 (enExample) | ||
| JP2017523781A5 (enExample) | ||
| JP2019500414A5 (enExample) | ||
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 |